Radiotherapy for patients with esophageal cancer aged 80 years or older: A 16-year experience.
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
18
04
2022
accepted:
29
11
2023
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
ppublish
Résumé
Radiotherapy (RT) plays an important role in esophageal cancer (EC) patients aged ≥80 years. However, the survival modality and prognostic factors remain poorly understood. Thus, this study aimed to evaluate the tolerance and long-term overall survival (OS) of patients aged ≥80 years who were diagnosed with EC and underwent definitive RT. A total of 213 consecutive patients with EC over 80 years old who were treated with curative intent RT between February 1999 and December 2015 at our institution were retrospectively reviewed. The clinical prognostic variables were analyzed against OS in univariate analyses using log-rank tests and in a multivariate model using Cox regression proportional hazards analysis. The median patient age was 82 (range: 80-94) years. Atotal of 192 patients (90.1%) completed the definitive RT (median: 60 Gy, range: 50-72 Gy), and 11 patients had grade 4 or higher acute toxicity, including esophagitis, a cardiac event, infections, and sudden death. Atotal of 168 deaths (78.9%) were observed with a median follow up of 47 months (range: 0-153 months). The OS rates were 50.3%, 17.6%, and 13.2% at 1, 3, and 5 years, respectively. Multivariable analysis identified that tumors located in the cervical and upper thorax, a shorter tumor lesion, RT treatment of 50-60Gy, and a better response to treatment were the factors associated with longer OS. Definitive RT could be considered as an effective treatment for patients with EC who are older than 80 years, and 50-60 Gy seems to be a reasonable dose for these patients.
Identifiants
pubmed: 38687940
doi: 10.4103/jcrt.jcrt_833_22
pii: 01363817-202420020-00023
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
678-683Informations de copyright
Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.
Références
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
N H, Noone AM, Krapcho M, Miller D, Bishop K, SF A, et al. SEER Cancer Statistics Review, 1975-2013: National Cancer Institute. Bethesda, MD;2016 [updated based on November 2015 SEER data submission, posted to the SEER web site, April 2016] Available from: http://seer.cancer.gov/csr/1975_2013/ .
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
Arias E United States life tables, 2000. Natl Vital Stat Rep 2002;51:1–38.
Crane LM, Schaapveld M, Visser O, Louwman MW, Plukker JT, van Dam GM Oesophageal cancer in The Netherlands: Increasing incidence and mortality but improving survival. Eur J Cancer 2007;43:1445–51.
Chen R, Zheng R, Zhang S, Wang S, Sun K, Zeng H, et al. Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data. J Natl Cancer Center 2023;3:21–7.
Oakley B, Lamb C, Vohra R, Catton J Achieving long term survival in oesophagectomy patients aged over 75. Ann Med Surg (Lond) 2016;9:15–21.
Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, et al. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol 2014;140:867–72.
Nallapareddy S, Wilding GE, Yang G, Iyer R, Javle M Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res 2005;25:3055–60.
Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008;99:1586–92.
Mak RH, Mamon HJ, Ryan DP, Miyamoto DT, Ancukiewicz M, Kobayashi WK, et al. Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Dis Esophagus 2010;23:316–23.
Tanisada K, Teshima T, Ikeda H, Abe M, Owen JB, Hanks GE, et al. A preliminary outcome analysis of the Patterns of Care Study in Japan for esophageal cancer patients with special reference to age: Non surgery group. Int J Radiat Oncol Biol Phys 2000;46:1223–33.
Yamakawa M, Shiojima K, Takahashi M, Saito Y, Matsumoto H, Mitsuhashi N, et al. Radiation therapy for esophageal cancer in patients over 80 years old. Int J Radiat Oncol Biol Phys 1994;30:1225–32.
Hishikawa Y, Kurisu K, Taniguchi M, Kamikonya N, Miura T Radiotherapy for carcinoma of the esophagus in patients aged eighty or older. Int J Radiat Oncol Biol Phys 1991;20:685–8.
Kawashima M, Ikeda H, Yorozu A, Niibe H, Teshima T, Fuwa N, et al. Clinical features of esophageal cancer in the octogenarian treated by definitive radiotherapy: A multi-institutional retrospective survey. Jpn J Clin Oncol 1998;28:301–7.
Greene FL, Page DL, Fleming ID AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
Tsurumaru D, Hiraka K, Komori M, Shioyama Y, Morita M, Honda H Role of barium esophagography in patients with locally advanced esophageal cancer: Evaluation of response to neoadjuvant chemoradiotherapy. Radiol Res Pract 2013 2013 502690 doi: 10.1155/2013/502690.
doi: 10.1155/2013/502690
Wan J, Xiao AQ, Gao SZ, Guo BZ, Wang YD, Zhou DA, et al. Criteria of evaluation of immediate response of radiation therapy for esophageal carcinoma-report on 1000 patients. Chinese J Radiation Oncol 1989;4:205–7.
Sidhu MS, Paul D, Jain S, Brar GS, Sood S, Jain K Prognostic factor for recurrence in esophagus cancer patients who underwent surgery for curative intent: A single-institution analysis. J Cancer Res Ther 2021;17:1376–81.
Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus 2015;12:1–30 doi: 10.1007/s10388-014-0465-1.
doi: 10.1007/s10388-014-0465-1
Thompson WM Esophageal cancer. Int J Radiat Oncol Biol Phys 1983;9:1533–65.
Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg 2011;91:887–93.
Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, et al. Esophageal tumor length is independently associated with long-term survival. Cancer 2009;115:508–16.
Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM Tumor length as a prognostic factor in esophageal malignancy: Univariate and multivariate survival analyses. J Surg Oncol 2006;93:258–67.
Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, et al. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:656–64.
Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006;78:236–44.
Ghosh-Laskar S, Mummudi N, Kumar S, Chandre M, Mishra S, Tibdewal A, et al. Definitive radiation therapy with dose escalation is beneficial for patients with squamous cell cancer of the esophagus. J Cancer Res Ther 2022;18 Suppl S285–92.
Hu D, Zhang M, Peng Z Prognostic value and functional bioinformatic analysis of spindle- and kinetochore-associated protein 1 in stage IIA esophageal squamous cell carcinoma. J Cancer Res Ther 2020;16:1157–64.